Millendo Therapeutics, Inc. announced that the proposed merger with OvaScience, Inc. has closed, following the approval of OvaScience's stockholders received on December 4, 2018. The combined company will operate under the leadership of Millendo's President and Chief Executive Officer, Julia Owens, and will be headquartered in Ann Arbor, Michigan. The board of directors is comprised of eight members, including Carol Gallagher, Pharm.

D., Habib Dable, Mary Lynne Hedley, Ph.D., James Hindman, John Howe, M.D., Carole Nuechterlein, J.D., Julia Owens, Ph.D., and Randall Whitcomb, M.D. Dr. Gallagher is the new Chairman of the board of directors.